Clinical trial
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
NCT01898273 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
- Lead sponsor
- Cellectar Biosciences, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 28, 2014
- Completion date
- December 31, 2015
- Enrollment
- 7 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.